PT2323642E - Utilização de edta+trometamina ou de fotoiativadores, associados a riboflavina para reticulação da córnea no tratamento de ceratocone ou de outros distúrbios ectásicos da córnea - Google Patents

Utilização de edta+trometamina ou de fotoiativadores, associados a riboflavina para reticulação da córnea no tratamento de ceratocone ou de outros distúrbios ectásicos da córnea Download PDF

Info

Publication number
PT2323642E
PT2323642E PT97484943T PT09748494T PT2323642E PT 2323642 E PT2323642 E PT 2323642E PT 97484943 T PT97484943 T PT 97484943T PT 09748494 T PT09748494 T PT 09748494T PT 2323642 E PT2323642 E PT 2323642E
Authority
PT
Portugal
Prior art keywords
corneal
photoenhancers
keratoconus
tromethamine
riboflavin
Prior art date
Application number
PT97484943T
Other languages
English (en)
Inventor
Giovanni Cavallo
Marcello Stagni
Edoardo Stagni
Massimo Filippello
Eugenio Sodo
Original Assignee
Sooft Italia S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2323642(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sooft Italia S P A filed Critical Sooft Italia S P A
Publication of PT2323642E publication Critical patent/PT2323642E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PT97484943T 2008-08-28 2009-08-27 Utilização de edta+trometamina ou de fotoiativadores, associados a riboflavina para reticulação da córnea no tratamento de ceratocone ou de outros distúrbios ectásicos da córnea PT2323642E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM2008A000472A IT1393402B1 (it) 2008-08-28 2008-08-28 Uso di enhancer eventualmente con riboflavina, nonche' relative composizioni oftalmiche per cross-linking corneale del cheratocono o di altre patologie ectasiche corneali

Publications (1)

Publication Number Publication Date
PT2323642E true PT2323642E (pt) 2014-05-15

Family

ID=40679354

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97484943T PT2323642E (pt) 2008-08-28 2009-08-27 Utilização de edta+trometamina ou de fotoiativadores, associados a riboflavina para reticulação da córnea no tratamento de ceratocone ou de outros distúrbios ectásicos da córnea

Country Status (18)

Country Link
US (1) US20110152219A1 (pt)
EP (1) EP2323642B1 (pt)
JP (1) JP2012500844A (pt)
KR (1) KR20110046567A (pt)
CN (1) CN102164592B (pt)
AU (1) AU2009286285B2 (pt)
BR (1) BRPI0910368B8 (pt)
CL (1) CL2011000378A1 (pt)
DK (1) DK2323642T3 (pt)
EA (2) EA022055B1 (pt)
ES (1) ES2460578T3 (pt)
IL (1) IL211448A (pt)
IT (1) IT1393402B1 (pt)
MX (2) MX2011002234A (pt)
PE (1) PE20110287A1 (pt)
PL (1) PL2323642T3 (pt)
PT (1) PT2323642E (pt)
WO (1) WO2010023705A1 (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009073213A1 (en) 2007-12-05 2009-06-11 Avedro, Inc. Eye therapy system
WO2010039854A1 (en) 2008-09-30 2010-04-08 Neal Marshall Eye therapy system
US9707126B2 (en) 2009-10-21 2017-07-18 Avedro, Inc. Systems and methods for corneal cross-linking with pulsed light
WO2011050164A1 (en) 2009-10-21 2011-04-28 Avedro, Inc. Eye therapy
JP6377906B2 (ja) 2010-03-19 2018-08-22 アヴェドロ・インコーポレーテッドＡｖｅｄｒｏ，Ｉｎｃ． 眼治療を適用およびモニターするためのシステム
US20120289886A1 (en) * 2010-04-13 2012-11-15 Avedro, Inc. Controlled application of cross-linking agent
US20110280763A1 (en) * 2010-05-17 2011-11-17 Abbott Medical Optics Inc. Light-activated disinfection system
IT1400982B1 (it) 2010-07-05 2013-07-05 Pinelli Collirio osmotico trans-epiteliale per la cura del cheratocono.
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
EA022306B1 (ru) 2011-01-12 2015-12-30 Соофт Италия Спа Устройство и способ подачи рибофлавина в роговицу путем ионофореза для лечения кератоконуса
MX2013008042A (es) 2011-01-12 2013-09-16 Sooft Italia Spa Suministro a la cornea de agentes de reticulacion mediante iontoforesis, para el tratamiento del queratocono y composiciones oftalmicas relacionadas.
US9044308B2 (en) 2011-05-24 2015-06-02 Avedro, Inc. Systems and methods for reshaping an eye feature
WO2012167260A2 (en) 2011-06-02 2012-12-06 Avedro, Inc. Systems and methods for monitoring time based photo active agent delivery or photo active marker presence
ITRM20110560A1 (it) * 2011-10-25 2013-04-26 Sooft Italia Spa Migliorata composizione di cross-linking per il trattamento del cheratocono mediante iontoforesi
RU2481809C1 (ru) * 2011-12-21 2013-05-20 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения кератэктазии после лазик
EP2830637A4 (en) 2012-03-29 2016-03-16 Cxl Ophthalmics Llc COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES RELATED TO OXIDATIVE STRESS
WO2013148896A1 (en) * 2012-03-29 2013-10-03 Cxl Ophthalmics, Llc Ocular treatment solutions, delivery devices and delivery augmentation methods
WO2013148895A1 (en) 2012-03-29 2013-10-03 Cxl Ophthalmics, Llc Ocular cross-linking system and method for sealing corneal wounds
RU2487691C1 (ru) * 2012-04-12 2013-07-20 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Способ лечения кератоконуса
WO2014114359A1 (en) * 2013-01-28 2014-07-31 Wavelight Gmbh Apparatus for corneal crosslinking
EP3858356A3 (en) * 2013-05-19 2021-12-01 Avedro, Inc. Systems, methods, and compositions for cross-linking
WO2014205145A1 (en) 2013-06-18 2014-12-24 Avedro, Inc. Systems and methods for determining biomechanical properties of the eye for applying treatment
US9498114B2 (en) 2013-06-18 2016-11-22 Avedro, Inc. Systems and methods for determining biomechanical properties of the eye for applying treatment
RU2542799C1 (ru) * 2013-10-29 2015-02-27 Игорь Борисович Медведев Способ лечения кератоконуса роговицы
US9931199B2 (en) * 2014-05-05 2018-04-03 Roberto Gustavo ALBERTAZZI Methods and apparatus for treating keratoconus
US10195081B1 (en) 2014-05-12 2019-02-05 Gholam A. Peyman Method of prevention of capsular opacification and fibrosis after cataract extraction and/or prevention of fibrosis around a shunt or stent after glaucoma surgery
US10278920B1 (en) 2014-05-12 2019-05-07 Gholam A. Peyman Drug delivery implant and a method using the same
US10314690B1 (en) 2014-05-12 2019-06-11 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
US11565023B2 (en) 2014-05-12 2023-01-31 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
US11666777B2 (en) 2014-05-12 2023-06-06 Gholam A. Peyman Photodynamic therapy technique for preventing damage to the fovea of the eye or another body portion of a patient
US11648261B2 (en) 2014-05-12 2023-05-16 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
US9427355B1 (en) * 2014-05-12 2016-08-30 Gholam A. Peyman Corneal transplantation with a cross-linked cornea
US10881503B2 (en) 2014-05-12 2021-01-05 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
US11045352B2 (en) 2014-05-12 2021-06-29 Gholam A. Peyman Methods for treatment of dry eye and other acute or chronic inflammatory processes
US9744029B1 (en) 2014-05-12 2017-08-29 Gholam A. Peyman Method of preventing capsular opacification and fibrosis utilizing an accommodative intraocular lens implant
US10709546B2 (en) 2014-05-12 2020-07-14 Gholam A. Peyman Intracorneal lens implantation with a cross-linked cornea
US10583221B2 (en) 2014-05-12 2020-03-10 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
US9937033B1 (en) 2014-05-12 2018-04-10 Gholam A. Peyman Corneal lenslet implantation with a cross-linked cornea
US11338059B2 (en) 2014-05-12 2022-05-24 Gholam A. Peyman Method of corneal and scleral inlay crosslinking and preservation
US10206569B1 (en) 2014-05-12 2019-02-19 Gholam A. Peyman Corneal intraocular pressure sensor and a surgical method using the same
US10925889B2 (en) 2014-05-12 2021-02-23 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
US11259914B2 (en) 2014-05-12 2022-03-01 Gholam A. Peyman Molding or 3-D printing of a synthetic refractive corneal lenslet
CN107205845B (zh) 2014-10-27 2020-03-31 艾维德洛公司 用于眼的交联治疗的系统和方法
US10114205B2 (en) 2014-11-13 2018-10-30 Avedro, Inc. Multipass virtually imaged phased array etalon
EP3827792A1 (en) 2015-04-24 2021-06-02 Avedro, Inc. Systems and methods for photoactivating a photosensitizer applied to an eye
PT3288588T (pt) 2015-04-29 2018-11-13 Sooft Italia Spa Agentes de reticulação melhorados de fibras de colagénio para uso no tratamento da ectasia corneana
WO2016191342A1 (en) 2015-05-22 2016-12-01 Avedro, Inc. Systems and methods for monitoring cross-linking activity for corneal treatments
CN108025011A (zh) * 2015-07-21 2018-05-11 艾维德洛公司 用光敏剂治疗眼睛的系统和方法
CN105256059B (zh) * 2015-11-20 2019-01-18 山东省眼科研究所 Tuba3d基因在制备圆锥角膜诊断制品中的应用
ITUB20160237A1 (it) 2016-01-26 2017-07-26 Vision Engineering Italy Soc A Responsabilita Limitata Apparato di controllo del dosaggio di un agente cromoforo in un tessuto corneale e procedimento per dosare un agente cromoforo in un tessuto corneale
EP3442481B1 (en) 2016-04-13 2023-06-28 Avedro, Inc. Systems for delivering drugs to an eye
US20180236077A1 (en) * 2017-02-21 2018-08-23 Avedro, Inc. Formulations for eye treatments
AU2019231257A1 (en) 2018-03-05 2020-10-15 Avedro, Inc. System for eye tracking during eye treatment
US11766356B2 (en) 2018-03-08 2023-09-26 Avedro, Inc. Micro-devices for treatment of an eye
US12016794B2 (en) 2018-10-09 2024-06-25 Avedro, Inc. Photoactivation systems and methods for corneal cross-linking treatments
US11707518B2 (en) 2019-04-28 2023-07-25 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
WO2021026405A1 (en) 2019-08-06 2021-02-11 Avedro, Inc. Photoactivation systems and methods for corneal cross-linking treatments
CN110314034B (zh) * 2019-08-08 2021-12-03 南京市第一医院 一种可实现个性治疗的角膜交联装置
US11458220B2 (en) 2020-11-12 2022-10-04 Singletto Inc. Microbial disinfection for personal protection equipment
CN115177729B (zh) * 2022-08-03 2023-09-26 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) 肾上腺素受体激动剂在制备圆锥角膜交联促渗剂中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
EP1061873B1 (en) * 1998-03-09 2005-11-02 Ista Pharmaceuticals, Inc Use of glyceraldehyde as corneal hardening agents
US6174524B1 (en) 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
AU2001249984B2 (en) * 2000-02-11 2005-05-26 The General Hospital Corporation Photochemical tissue bonding
JP5583310B2 (ja) * 2002-12-20 2014-09-03 チャクシュ・リサーチ・インコーポレーテッド 眼球の症状の予防及び治療のための眼科用製剤
ITRM20050443A1 (it) * 2005-08-12 2007-02-13 Opocrin Spa Preparati oftalmici a base di polisaccaridi mucoadesivi con capacita' riepitelizzante della cornea.
US20120203161A1 (en) * 2009-08-12 2012-08-09 Seros Medical, Llc Deuterated water and riboflavin solution for extending singlet oxygen lifetimes in treatment of ocular tissue and method of use

Also Published As

Publication number Publication date
EA022055B1 (ru) 2015-10-30
MX358176B (es) 2018-08-08
WO2010023705A1 (en) 2010-03-04
EP2323642B1 (en) 2014-02-19
AU2009286285A1 (en) 2010-03-04
IL211448A (en) 2016-05-31
MX2011002234A (es) 2011-04-05
EP2323642A1 (en) 2011-05-25
PL2323642T3 (pl) 2014-07-31
CN102164592B (zh) 2015-09-23
CL2011000378A1 (es) 2011-06-10
EA023607B1 (ru) 2016-06-30
JP2012500844A (ja) 2012-01-12
ITRM20080472A1 (it) 2010-02-28
CN102164592A (zh) 2011-08-24
EA201100393A1 (ru) 2011-10-31
US20110152219A1 (en) 2011-06-23
AU2009286285B2 (en) 2015-03-26
IL211448A0 (en) 2011-05-31
PE20110287A1 (es) 2011-05-15
IT1393402B1 (it) 2012-04-20
BRPI0910368A2 (pt) 2015-10-13
EA201300272A1 (ru) 2013-07-30
DK2323642T3 (da) 2014-05-05
BRPI0910368B8 (pt) 2021-05-25
ES2460578T3 (es) 2014-05-13
KR20110046567A (ko) 2011-05-04
BRPI0910368B1 (pt) 2020-01-28

Similar Documents

Publication Publication Date Title
PL2323642T3 (pl) Zastosowanie układu EDTA + trometamina lub środków foto-wzmacniających, przyłączonych do ryboflawiny do sieciowania rogówki w leczeniu stożka rogówki lub innych zaburzeń związanych z rozszerzeniem rogówki
HK1153926A1 (en) Purin derivatives for use in the treatment of fab-related diseases fab-
EP2624916A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE OBESE, NEOVASCULARIZATION AND RELATED DISEASES
PL3135672T3 (pl) Kompozycje i sposoby leczenia zaburzeń używania alkoholu, bólu i innych chorób
PL2838539T3 (pl) Składniki estrogenowe do zastosowania w leczeniu zaburzeń neurologicznych
EP2558104A4 (en) METHOD AND OPHTHALMIC COMPOSITION FOR TREATING RETINAL DISEASE
ZA201206898B (en) Piperazinotriazines as pi3k inhibitors for use in the treatment antiproliferatiive disorders
HK1252981A1 (zh) 作為用於治療數種疾病如抑鬱症、糖尿病和帕金森病的taar調節劑的吡唑甲酰胺衍生物
PL2861568T3 (pl) Aminy trzeciorzędowe do zastosowania w leczeniu zaburzeń serca
EP2654434A4 (en) METHOD FOR TREATING TISSUE DISEASES, TROUBLES AND INJURIES
IL228891A0 (en) Use of 3-carboxy-m-ethyl n,n--dimethylpropane-1-aminium salts in the treatment of cardiovascular disease
UA44395U (ru) Применение тиоцетама в качестве диуретического средства с мягким мочегонным действием в комплексном лечении
HUE040124T2 (hu) Diaminooxidázt tartalmazó helyi alkalmazású kompozíciók, magas hisztamin-szinttel társult, a fájdalom növekedésével járó betegségek kezelésére vagy megelõzésére
IL249871B (en) 2-(2-methylamino-pyrimidin-4-yl)-h1-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amine for use In the treatment of pain due to osteoarthritis
IL190528A0 (en) Synergistic drug combinations for the treatment of ocular surface disorders
UA97741C2 (ru) Способ восстановления кожных покровов при глубоких распространенных ожогах микроаутодермотрансплантатами